TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
← New search
Home›Stocks›PHVS
PHVS logo

PHVS

Pharvaris N.V.

Next earnings Aug 10, 2026 (after close) · consensus $-0.68 EPS

Sell
$33.86
▼ -2.45%
$33.86▲ +99.18%
over 1Y
L $17.00H $34.71
Today-2.4%
1W+1.7%
1M+16.8%
3M+18.6%
YTD+27.9%
1Y+99.2%
OverviewValuationQualityFilings
Rating
Sell
Quality
A
Valuation
Fair value
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 20 analysts
Strong Buy

Mixed signals in the latest filings.

Pharvaris N.V. shows limited reported revenue.

On these fundamentals, PHVS screens as SELL on the SEC figures.

Is PHVS a buy? The one-page verdict, explained →

The options angle

model · matches our verdict
Bear put spread~60d expiry
  • Long put 34 @ ~2.23 est
  • Short put 30 @ ~0.70 est
debit $153max +$247max −$153BE 32.47

SELL verdict, defined risk: profits into weakness down to the short strike; max loss is the net debit.

Open in the calculator →

Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.

Financials · annual, by fiscal year

No income data filed.

10-year statements — income, cash flow, balance sheet & CSV export →

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$2.37B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—

Quality & risk

ROIC (est.)—
Free cash flow—
Total debt—
Net cash—

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+19.9%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Recent filings

all on EDGAR ↗
4Period ending 2026-06-292026-07-01open ↗4Period ending 2026-06-292026-07-01open ↗144Filing2026-06-30open ↗144Filing2026-06-30open ↗144Filing2026-06-30open ↗4Period ending 2026-06-252026-06-29open ↗4Period ending 2026-06-292026-06-29open ↗4Period ending 2026-06-252026-06-29open ↗144Filing2026-06-29open ↗144Filing2026-06-29open ↗144Filing2026-06-29open ↗144Filing2026-06-26open ↗

Quality score

A
ValueGrowthProfitHealthMom.
Value—
Growth—
Profitability—
Financial health—
MomentumA
17.9852-week34.71
Revenue
—
Net margin
—
ROE
—
P/E
—

SEC fundamentals

Frequently asked

Is Pharvaris N.V. (PHVS) a buy?
PHVS currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.
What is Pharvaris N.V.'s quality score?
PHVS scores 83.99465264492767/100 (grade A) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001830487, latest 4 filed 2026-07-01) · EODHD · as of 7/5/2026, 3:03:40 AM.

›About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice

Rule-based analysis, generated automatically from SEC filing data.

Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 4, 2026, 11:03 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Held by tracked funds

Form 13F · SEC · quarterly
Viking Global3.65M sh$103M

As of each fund’s latest quarterly 13F — a delayed snapshot, not a live position. All tracked funds →

Recent news

market news →
Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026Bullish
globenewswire.com· 2026-05-29
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of SharesBullish
finance.yahoo.com· 2026-05-19
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for InvestorsBullish
finance.yahoo.com· 2026-05-19
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for InvestorsBullish
nasdaq.com· 2026-05-19
Pharvaris Chief Medical Officer Sells 14,000 Shares for $427,000Bullish
finance.yahoo.com· 2026-05-11
For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming NextBullish
finance.yahoo.com· 2026-04-30

Vs tracked universe

compare →

1195 tracked peers · median

TENK Score84 vs 67
Revenue growth— vs 7.5%
Net margin— vs 10.0%
Return on equity— vs 12.0%
P/E— vs 26.2